Evaluacion positiva de medicamentos: octubre, noviembre y diciembre 2019
Aparicio Hernández, R; García Luque, A; Granda Lobato, P; Correa Pérez, A.
Sanid. mil
; 76(1): 19-24, ene.-mar. 2020.
Artigo em Espanhol | IBECS (Espanha) | ID: ibc-193136
Documentos relacionados
Estimation and approximation approaches for biosimilar index based on reproducibility probability.
Statistical assessment of biosimilarity based on relative distance between follow-on biologics.
A General Propensity Score for Signal Identification Using Tree-Based Scan Statistics.
A bibliometric analysis of the clinical development of drugs in Norway for the year 2000.
Comparability of critical quality attributes for establishing biosimilarity.
Impact of variability on the choice of biosimilarity limits in assessing follow-on biologics.
An adapted F-test for homogeneity of variability in follow-on biological products.
Medication package inserts do not present adequate information on potential risks for older adults in Brazil
Evaluating the impact of database heterogeneity on observational study results.
Statistical Approaches to Assess Biosimilarity from Analytical Data.